RELATIONSHIP BETWEEN MENTAL ILLNESS AND MENTAL WELLBEING
Dr Matthew Iasiello, Head of Data and Research Translation, Be Well Co,
SAHMRI (South Australian Health and Medical Research Institute) &
Post Doctoral Researcher, University of Adelaide
RESEARCHER PROFILE
Filmed in Adelaide, South Australian | December 2024
Since 2015, Dr Matthew Iasiello has been working on the development and dissemination of mental wellbeing interventions across the Australian community at the South Australian Health and Medical Research Institute (SAHMRI). His PhD research was designed specifically to strengthen the translational work conducted by SAHMRI, and to solve problems that represented gaps in the literature that were arising when delivering mental wellbeing interventions into the community. The impact and relevance of Dr Iasiello’s work has been demonstrated with invited presentations at international academic conferences, and multiple media stories with significant online engagements.
Dr Iasiello’s research investigates the dual-continua model, an innovative model of mental health. The dual-continua model of mental health suggests that mental illness and mental wellbeing reflect distinct continua, rather than the extreme ends of a single spectrum. This novel conceptualisation of the relationship between mental illness and mental wellbeing has significant implications in the way we promote mental health, and prevent, treat, and recover from mental illness. However, little is known about the evidence validating the model, and whether this evidence supports the implications that have been proposed in the literature.
Dr Iasiello’s PhD project synthesises the relevant evidence supporting the model, provides further evidence of the role of mental wellbeing in the recovery of mental illness, and addresses important limitations in the current assessment of mental wellbeing in the context of psychological distress and mental illness.
He is engaged in the development of mental wellbeing services and products that emerge directly from the new knowledge generated from his PhD, translated into the community via SAHMRI. This has resulted in the development and evaluation of the Be Well Plan (https://www.bewellco.io/bwt), and evidence-based wellbeing intervention (over 5,000 participants since 2020), and the Be Well Tracker https://www.bewellco.io/be-well-plan, a free online assessment platform that Australians can use to assess and monitor their mental health (20,000 users since 2019).
-
Genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia
Prof Deborah White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.
-
Unnecessary tests and treatments in low value critical care
Dr Gerben Keijzers is a Senior Staff Specialist Emergency Physician at the Gold Coast University Hospital Emergency Department. His research focus includes low-value care, which is in the area of unnecessary tests and treatments with minimal benefits. Dr Keijzers has contributed to over 100 publications and more than 20 grant applications. Through his involvement in multi-site collaborative research projects, he encourages critical thinking and curiosity among clinical staff, striving to enhance both patient care and the efficiency of healthcare resources.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
